Compare Incyte Corporation (INCY) vs Super Micro Computer Inc (SMCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Super Micro Computer Inc — how do they compare? Incyte Corporation trades at $118.01 (market cap $23.11B), while Super Micro Computer Inc trades at $25.32 (market cap $15.41B). The key difference: Incyte Corporation is the larger of the two by market cap, and Incyte Corporation is trading nearer its 52-week high, Super Micro Computer Inc nearer its low. Which is the better fit depends on your goals.
| INCY | SMCI | |
|---|---|---|
Market Cap | $23.11B | $15.41B |
Sector | Health | Technology |
52-Week High | $118.52 | $60.71 |
52-Week Low | $67.38 | $20.53 |
Enterprise Value | $19.13B | $22.93B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
Super Micro Computer (SMCI) trades at $23.83, down 1.41% on the day, with a bearish technical signal despite recent earnings beats. Valuation ratios appear attractive with a P/E of 12.73 and P/S of 0.48, but cash flow trends show strain with a projected negative net cash flow of $1.2B in 2026. The company is expanding its liquid cooling portfolio for AI data centers, but faces investor concerns over inventory growth and competitive pressures.
The outlook is mixed: strong AI demand and low valuations offer upside potential, but cash flow volatility, rising competition, and a Taiwan regulatory probe pose significant risks. Analyst consensus is cautious with a $36.71 price target, reflecting 54% upside, yet hold ratings dominate at 56% due to near-term execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Super Micro Computer Inc
Super Micro Computer, Inc., commonly known as Supermicro, is a leading provider of high-performance and high-efficiency server technology and innovation. The company specializes in designing, manufacturing, and selling advanced server, storage, and networking solutions, primarily for data centers, cloud computing, artificial intelligence, and 5G/Edge computing markets. SMCI's modular architecture allows for the rapid delivery of customized and purpose-built solutions, making it a key player in the enterprise computing and specialized AI infrastructure space.
Read more on SMCI →
